Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study
Author:
Publisher
Elsevier BV
Subject
Cell Biology,Dermatology,Molecular Biology,Biochemistry
Reference25 articles.
1. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies;Augustin;J Eur Acad Dermatol Venereol,2020
2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
3. Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy;Brezinski;PLoS One,2012
4. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis;Egeberg;J Am Acad Dermatol,2019
5. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis;Egeberg;Br J Dermatol,2018
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study;Journal of Dermatological Treatment;2024-09-04
2. Research trends and hotspots in biologics for plaque psoriasis: A bibliometric study from 2004 to 2023;Heliyon;2024-08
3. Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study;Journal of the European Academy of Dermatology and Venereology;2024-07-25
4. Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-interleukin-17A monoclonal antibody: an observational study;Scientific Reports;2024-07-02
5. Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan;Experimental Dermatology;2024-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3